Comparing Sonoma Pharmaceuticals (SNOA) and BioMarin Pharmaceutical (BMRN)

Sonoma Pharmaceuticals (NASDAQ: SNOA) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.

Analyst Ratings

This is a summary of current recommendations and price targets for Sonoma Pharmaceuticals and BioMarin Pharmaceutical, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sonoma Pharmaceuticals 0 1 1 0 2.50
BioMarin Pharmaceutical 0 5 16 1 2.82

Sonoma Pharmaceuticals currently has a consensus target price of $10.50, indicating a potential upside of 89.53%. BioMarin Pharmaceutical has a consensus target price of $114.65, indicating a potential upside of 27.33%. Given Sonoma Pharmaceuticals’ higher possible upside, analysts plainly believe Sonoma Pharmaceuticals is more favorable than BioMarin Pharmaceutical.

Valuation and Earnings

This table compares Sonoma Pharmaceuticals and BioMarin Pharmaceutical’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sonoma Pharmaceuticals $12.82 million 1.90 $9.27 million ($1.99) -2.78
BioMarin Pharmaceutical $1.12 billion 14.16 -$630.21 million ($0.83) -108.48

Sonoma Pharmaceuticals has higher earnings, but lower revenue than BioMarin Pharmaceutical. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.


This table compares Sonoma Pharmaceuticals and BioMarin Pharmaceutical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sonoma Pharmaceuticals 47.68% -43.23% -35.78%
BioMarin Pharmaceutical -12.45% -4.60% -3.09%

Risk and Volatility

Sonoma Pharmaceuticals has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500.

Institutional & Insider Ownership

9.2% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 99.0% of BioMarin Pharmaceutical shares are held by institutional investors. 13.3% of Sonoma Pharmaceuticals shares are held by company insiders. Comparatively, 1.9% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.


BioMarin Pharmaceutical beats Sonoma Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc., formerly Oculus Innovative Sciences, Inc., is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid. Microcyn is a small-molecule oxychlorine compound with antimicrobial and anti-inflammatory properties that, in clinical settings, reduces itch and pain associated with dermal irritations and wounds, such as sores, injuries and ulcers of dermal tissue. Lipogrid Technology contains selected lipids and a lipid precursor designed to penetrate the bilayers of the skin by blending with the natural lipid building blocks. Its products serve over five million patients across the globe by reducing infections, itch, pain, scarring and inflammatory responses. Its products are sold throughout the United States and internationally.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply